Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer

Huang,Zhi-Heng; Tian,Xing-Song; Li,Rong; Wang,Xian-Ming; Wen,Wen; Guan,Hong; Yang,Ya-Jie

doi:10.3892/etm.2011.395

Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer

Authors:
- Zhi-Heng Huang
- Xing-Song Tian
- Rong Li
- Xian-Ming Wang
- Wen Wen
- Hong Guan
- Ya-Jie Yang
View Affiliations

Affiliations: Department of Breast Surgery, Shandong Province Hospital, Shandong University, Jinan 250012, P.R. China, Department of Breast Surgery, Second People's Hospital of Shen Zhen, Shen Zhen University, Shen Zhen 518035, P.R. China, Department of Pathology, Second People's Hospital of Shen Zhen, Shen Zhen University, Shen Zhen 518035, P.R. China
Published online on: November 28, 2011 https://doi.org/10.3892/etm.2011.395
Pages: 331-335

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with locally advanced breast cancer (LABC) commonly have an unfavorable prognosis. A molecular predictor for the identification of at-risk patients is urgently required. Thymidine kinase 1 in serum (S-TK1) is an enzyme involved in the synthesis of DNA precursors. In studies using immunohistochemistry, it was reported to be a more useful proliferation marker than Ki-67 in breast, lung and colorectal carcinoma. In the present study, we extended the research of prior breast carcinoma studies by postulating that in patients with LABC, overexpression of S-TK1 following neoadjuvant chemotherapy predicts cancer outcome. An experimental design consisting of 48 patients with LABC was prospectively constructed and analyzed. All patients received neoadjuvant chemotherapy and definitive surgical therapy. Study homogeneity was maintained by standardized treatment, surveillance and compliance protocols. The S-TK1 concentration was detected using the anti-TK1 chicken IgY antibody, using a dot-blot immuno-assay. After a median follow-up of 30 months, the results indicated a statistically significant trend (unadjusted). Patients with high S-TK1 overexpression had a significantly higher incidence of recurrence (P=0.006) and cancer death (P=0.0128) than those with low S-TK1 overexpression. A multivariate analysis provided identical results. The hazards ratio for developing recurrence in patients with higher S-TK1 expression was 6-7 times higher than the hazards ratio in patients with lower expression. In conclusion, our results indicate that a high S-TK1 concentration in sera from LABC patients receiving neoadjuvant chemotherapy is predictive of cancer outcome.

View Figures

View References

1.	GN HortobagyiComptehensive management of locally advanced breast cancerCancer6613871391199010.1002/1097-0142(19900915)66:14+%3C1387::AID-CNCR2820661414%3E3.0.CO;2-I2205369
2.	GN HortobagyiFC AmesAU BuzdarManagement of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer6225072516198810.1002/1097-0142(19881215)62:12%3C2507::AID-CNCR2820621210%3E3.0.CO;2-D3056604
3.	B FisherN GunduzEA SafferInfluence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasesCancer Res431488149219836831397
4.	B FisherJ BryantN WolmarkEffect of preoperative chemotherapy on the outcome of women with operable breast cancerJ Clin Oncol162672268519989704717
5.	S GobleHD BearEmerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questionsSurg Clin North Am83943971200310.1016/S0039-6109(03)00071-912875604
6.	JC ChangEC WootenA TsimelzonGene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerLancet362362369200310.1016/S0140-6736(03)14023-812907009
7.	SM SchollJY PiergaB AssselainBreast tumor response to primary chemotherapy predicts local and distant control as well as survivalEur J Cancer31A19691975199510.1016/0959-8049(95)00454-88562150
8.	VF SemiglazovEE TopuzovJL BavliPrimary chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancerAnn Ocol559159519947993833
9.	A MakrisTJ PowlesM DowsettPrediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomasClin Cancer Res359360019979815725
10.	L MauriacG MacGroganA AvrilNeoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institute Bergonie Bordeaux Groupe SeinAnn Oncol104752199910.1023/A:1008337009350
11.	JA van der HageCJ van der VeldeJP JulienPreoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902J Clin Oncol19422442372000
12.	CM HuZF ChangMitotic control of dTTP pool: a necessary or coincidence?J Biomed Sci14491497200710.1007/s11373-007-9175-117525869
13.	AS Al-MadhounW TjarksS ErikssonThe role of thymidine kinase in the activation of pyrimidine nucleoside analoguesMini Rev Med Chem4341350200415134537
14.	C WuR YangJ ZhouProduction and characterization of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1J Immunol Methods277157169200310.1016/S0022-1759(03)00062-012799048
15.	A GowdaJC ByrdUse of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemiaCurr Opin Hematol13266272200616755224
16.	BR MadewellSerum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphomaJ Vet Intern Med18595596200415515571
17.	RF DiR GiustolisiS LernerRetrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabineAnn Oncol12621625200110.1023/A:101113882559311432619
18.	MK SchwartzEnzymes as prognostic markers and therapeutic indicators in patients with cancerClin Chim Acta2067782199210.1016/0009-8981(92)90008-E1572080
19.	KL O’NeillF ZhangH LiThymidine kinase1 – a prognostic and diagnostic indicator in ALL and AML patientsLeukemia215605632007
20.	J ZhangQ JiaS ZouThymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patientsOncol Rep15455461200616391869
21.	R FujiwakiK HataM MoriyamaClinical value of thymidine kinase in patients with cervical carcinomaOncology614754200110.1159/00005535211474248
22.	D TiezziJ AndrateA Ribeiro-SilvaHER-2, p53, p21 and hormonal receptor protein expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combinationBMC Cancer736200710.1186/1471-2407-7-36
23.	S SingletaryM McNeeseG HortobagyiFeasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinomaCancer6928492852199210.1002/1097-0142(19920601)69:11%3C2849::AID-CNCR2820691134%3E3.0.CO;2-P1571916
24.	M AlassasQ ChuG BurtonNeoadjuvant chemotherapy in stage III breast cancerAm Surgeon71487492200516044927
25.	C IsaccsV StearnsDF HayesNew prognostic factors for breast cancer recurrenceSemin Oncol285367200110.1053/sonc.2000.2074211254867
26.	L GianniM ZambettiK ClarkGene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancerJ Clin Oncol2372657277200510.1200/JCO.2005.02.081816145055
27.	K HessK AndersonW SymmansPharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclophosphamide in breast cancerJ Clin Oncol2442364244200610.1200/JCO.2006.05.686116896004
28.	T SorlieC PerouC FanGene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancerMol Cancer Ther529142918200610.1158/1535-7163.MCT-06-012617121939
29.	J PiegaJ Reis-FilhoS CleatorMicro-array-based comparative genomic hybridization of breast cancer patients receiving neoadjuvant chemotherapyBr J Cancer96341351200710.1038/sj.bjc.6603483
30.	S PaikS ShakG TangA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med35128172826200410.1056/NEJMoa04158815591335
31.	T PalangieV MosseriJ MihuraPrognostic factors in inflammatory breast cancer and therapeutic implicationsEur J Cancer30A921927199410.1016/0959-8049(94)90115-57946584
32.	A HonkoopP van DiestJ de JongPrognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancerBr J Cancer77621626199810.1038/bjc.1998.999484820
33.	N HolmK ByrnesB LiElevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrenceJ Surg Res1415359200710.1016/j.jss.2007.03.01517574038